Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 9/20 | 0.61 |
| ▸ | PKLR | P30613 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989734 | 0.92 | CA12 (0.56) | PKMPKLRNPC1RAB9APTGS1 | |
| SCHEMBL2005036 | 0.88 | CA2 (0.74) | PKMPKLRNPC1RAB9APTGS1 | |
| SCHEMBL2224714 | 0.83 | PKM (0.65) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL6153109 | 0.83 | CA2 (0.68) | NPC1RAB9APTGS1PTGS2CA12 | |
| SCHEMBL13195329 | 0.82 | CA2 (0.53) | PKMPKLRNPC1RAB9APTGS1 | |
| SCHEMBL13195327 | 0.82 | CA2 (0.53) | PKMPKLRNPC1RAB9APTGS1 | |
| SCHEMBL13195306 | 0.80 | CA2 (0.55) | PKMPKLRNPC1RAB9APTGS1 | |
| SCHEMBL13194642 | 0.80 | CA2 (0.51) | PKMPKLRNPC1RAB9APTGS1 | |
| SCHEMBL2986914 | 0.80 | PKM (0.66) | PKMPKLRNPC1RAB9AHTT | |
| SCHEMBL32670216 | 0.80 | PKM (0.61) | PKMPKLRNPC1RAB9APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | claimed |
| EP-2906216-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vitas Pharma Research Private Limited (IN) | 2015-08-19 | — | — | EP | claimed |
| WO-2014057415-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PVT LTD (IN) | 2014-04-17 | — | — | WO | claimed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| EP-0583960-B1 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | LILLY CO ELI (US) | 1997-05-21 | — | — | EP | claimed |
| US-5387681-A | Reacting a bicyclic aromatic compound with a complex of sulfur trioxide-N,N-dimethylformamide; water miscible, non-reactive solvent; thionyl halide | ELI LILLY AND COMPANY (US) | 1995-02-07 | — | — | US | claimed |
| EP-0583960-A2 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | ELI LILLY AND COMPANY (US) | 1994-02-23 | — | — | EP | claimed |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2023028077-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-14 | — | — | US | disclosed |
| US-9290512-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2015-04-16 | — | — | US | disclosed |
| CN-1013198-B | ANTI-TUMOUR SULFONYLUREA DERIV. PREPARING PROCESS | LILLY CO ELI (US) | 1991-07-17 | — | — | CN | disclosed |
| EP-0222475-B1 | SULFONYL UREAS WITH ANTI-TUMOUR ACTIVITY | ELI LILLY AND COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
| EP-0254577-B1 | SYNTHESIS OF BICYCLIC AROMATIC SULFONYL CHLORIDES | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0254577-A1 | Synthesis of bicyclic aromatic sulfonyl chlorides | ELI LILLY AND COMPANY (US) | 1988-01-27 | — | — | EP | disclosed |
| EP-0222475-A1 | Sulfonyl ureas with anti-tumour activity | ELI LILLY AND COMPANY (US) | 1987-05-20 | — | — | EP | disclosed |
| CN-86106428-A | Anti-tumor method and compound thereof | — | 1987-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105395-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK4 | PKM 4/4885PKLR 6/4885NPC1 4746/4885 |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | PKM 1251/4885PKLR 819/4885NPC1 2758/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | PKM 3806/4885PKLR 4273/4885NPC1 438/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | PKM 1251/4885PKLR 819/4885NPC1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.